Applicants are enclosing a "marked up" copy of a substitute specification which shows additions to and/or deletions from the original specification, as well as an "as is" substitute specification with all additions and/or deletions prior to this response. Furthermore, the "as is" substitute specification includes the same changes as are indicated in the marked up copy of the original specification showing additions and/or deletions. Therefore, the substitute specification, Applicants respectfully submit, meets the requirements of the Examiner and should be acceptable.

IN THE CLAIMS

184. (Thrice Amended) A method of treating a disease or condition involving underperfused tissue and pathological tissue in humans, said disease or condition selected from the group consisting of renal failure, cardiac insufficiency, hypertension and edema, the method comprising the administration of an effective amount of a diuretic agent for treating said disease or condition, and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts thereof and combinations thereof to facilitate the transport of the agent at a site to be treated by the agent passing through the tissue through the cell membranes into the individual cells to be treated, wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg and less than 1000mg.

Claims 11, 119-121 and 184-186 remain in the application. No new subject matter has been added.